Restoring blood-clotting ability: mouse study shows novel engineered coagulation factor could have promise for tackling anticoagulant side effects
In a novel study from the Children’s Hospital of Philadelphia and the University of Pennsylvania (both Philadelphia, PA, USA), a variant of coagulation factor Xa was able to reverse the anticoagulation effects of blood-thinning drugs in animal models and could be used for reversing the effects of FXa inhibitors.
Please sign in or register for FREE
Sign in to MedChemNet
Register to MedChemNet
MedChemNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.